

47th Global Nursing & Healthcare Conference

March 01-03, 2018 | London, UK

Considerations for creating a protocol for vedolizumab infusions

Deepti B Prajapati

New York University Langone Medical Center, USA

Vedolizumab (Entyvio [®]) is one of the several treatment options for the management of ulcerative colitis and Crohn's disease. It is a recombinant humanized anti-alpha-4-beta-7 integrin monoclonal antibody. This biologic immunotherapy is utilized in patients who have failed or achieved inadequate response to the different therapies currently available for these disease processes. Certain considerations include monitoring for Progressive multifocal leukoencephalopathy (PML) and liver injury. These are rare adverse effects and occurrences. A protocol for the safe administration of vedolizumab at NYU's Infusion Center is based on current prescribing guidelines.